Additionally, the examination of lipid metabolism has revealed the accumulation of neutral lipids in HCC CSCs following long-term treatment with sorafenib, accompanied by increased expression of the lipogenic transcription factor SREBP1c and enzymes involved in de novo lipid synthesis, including fatty acid synthase (FASN), ATP-citrate lyase (ACLY), and acetyl-CoA carboxylase (ACC) (18). The gene discussed is FASN; the disease is hepatocellular carcinoma.